ArticleNeurology2020
Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
John Breitner et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleNeurology2020
John Breitner et al.PubMed ↗Publisher ↗
No numbers read from the abstract.